Skip to main content
. 2022 Feb 17;13:829569. doi: 10.3389/fneur.2022.829569

Figure 1.

Figure 1

Comparison of the rate of decline of body mass index (BMI) and ALS Functional Rating Scale-Revised (ALSFRS-R) score between patients treated with mNGF + riluzole and patients treated with riluzole only. (A,B), comparison of BMI (A) and ALSFRS-R (B) score within different time periods between the two treatment groups. “1st period,” “2nd period,” and “3rd period” refer to the 3 months before first mouse nerve growth factor (mNGF) injection, the 3 months after first mNGF injection and the 3–6 months after mNGF injection, respectively, in patients treated with mNGF + riluzole, and refer to the corresponding time periods in the riluzole only group; (C,D), the change in BMI (C) and ALSFRS-R (D) score before and after the application of mNGF in several patients. Each curve of different color indicates an individual patient. “0” indicates the time point of the first mNGF injection; (E,F), comparison of the declining rate of BMI (E) and ALSFRS-R (F) score before (indicated by the pre-slope axis) and after (indicated by the post-slope axis) the use of mNGF. Red circles indicate the increase of declining rate after mNGF treatment and blue circles indicate decreased or unchanged declining rate after mNGF treatment. ALSFRS-R, ALS Functional Rating Scale-Revised; BMI, body mass index; mNGF, mouse nerve growth factor; n.s., not significant.